Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H32O5 |
| Molecular Weight | 376.4865 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 2 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCC[C@@H](O)\C=C\C1=C(/C=C/[C@@H](O)[C@@H](O)CCCC(O)=O)C=CC=C1
InChI
InChIKey=HEDVTGFTYROYFE-RREUNBNVSA-N
InChI=1S/C22H32O5/c1-2-3-4-10-19(23)15-13-17-8-5-6-9-18(17)14-16-21(25)20(24)11-7-12-22(26)27/h5-6,8-9,13-16,19-21,23-25H,2-4,7,10-12H2,1H3,(H,26,27)/b15-13+,16-14+/t19-,20+,21-/m1/s1
Benzo-lipoxin A4 as a bLXA4-ME also known as ClinRinse-1 participated in phase II clinical trials for the treatment of gingival diseases. It was shown that nano-proresolving medicines (NPRM) containing a lipoxin analog (benzo-lipoxin A4, bLXA4) was a mimetic of endogenous resolving mechanisms with potent bioactions. That offered a new therapeutic tissue-engineering approach for the treatment of chronic osteolytic inflammatory diseases.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
864516-86-9
Created by
admin on Sat Dec 16 09:29:35 GMT 2023 , Edited by admin on Sat Dec 16 09:29:35 GMT 2023
|
PRIMARY | |||
|
LXE89WJ787
Created by
admin on Sat Dec 16 09:29:35 GMT 2023 , Edited by admin on Sat Dec 16 09:29:35 GMT 2023
|
PRIMARY | |||
|
58185197
Created by
admin on Sat Dec 16 09:29:35 GMT 2023 , Edited by admin on Sat Dec 16 09:29:35 GMT 2023
|
PRIMARY | |||
|
DB12133
Created by
admin on Sat Dec 16 09:29:35 GMT 2023 , Edited by admin on Sat Dec 16 09:29:35 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD
